Friday, July 10, 2026

pharma · Chronic kidney disease · Advanced solid tumors

Bayer

Bayer is a pharma organization headquartered in Leverkusen, DE. Primary therapeutic focus areas include Chronic kidney disease, Advanced solid tumors, Heart failure due to systemic left ventricular systolic dysfunction,

Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE HQ
97,894 Employees
EMA registrant Type
Company details
Status
Public
HQ
Kaiser-Wilhelm-Allee, Leverkusen, North Rhine-Westphalia 51373, DE
Employees
97,894
Programs
47
Drugs
62
Patents
5

Quick answer

Bayer is a pharma organization headquartered in Leverkusen, DE. Primary therapeutic focus areas include Chronic kidney disease, Advanced solid tumors, Heart failure due to systemic left ventricular systolic dysfunction, Solid tumors harboring NTRK fusion, Chronic Kidney Disease. NovaPharmaNews links 47 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (24), phase 2 (13), phase 3 (8).

Company snapshot

Bayer AG (English: [/ˈbaɪ.ər/](en.wikipedia.org/wiki/Help:IPA/English), commonly pronounced [/ˈbeɪər/](en.wikipedia.org/wiki/Help:IPA/English); German: [[ˈbaɪɐ]](en.wikipedia.org/wiki/Help:IPA/Standard_) [ⓘ](en.wikipedia.org/wiki/File:De-Bayer.ogg)) is a German [multinational](en.wikipedia.org/wiki/Multinational_corp) [pharmaceutical](en.wikipedia.org/wiki/Pharmaceutical) and [biotechnology](en.wi

  • 47 active pipeline program(s) linked via ClinicalTrials.gov.
  • 5 US patent(s) indexed to this assignee profile.
  • 47 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Bayer. Not investment advice.

Recent coverage

Lead pipeline drugs

Active clinical programs

  • 19920 Proteinuria, Chronic kidney disease
    Phase 3
  • 20186 Treatment of children with chronic kidney disease and proteinuria
    Phase 3
  • 21177 Non-diabetic chronic kidney disease
    Phase 3
  • 21466 Heart failure due to systemic left ventricular systolic dysfunction
    Phase 3

Momentum

Proprietary activity score for Bayer.

0 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 0 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d

Recent activity

Latest pipeline, patent, and corporate events for Bayer.

  1. Clinical update

    22819 — Phase 1

  2. Clinical update

    22723 — Phase 1

  3. Clinical update

    22598 — Phase 1

  4. Clinical update

    22342 — Phase 1

  5. Clinical update

    BAY 94-9027/21824 — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Bayer?

    Bayer is a pharma organization headquartered in Leverkusen, DE. Primary therapeutic focus areas include Chronic kidney disease, Advanced solid tumors, Heart failure due to systemic left ventricular systolic dysfunction, Solid tumors harboring NTRK fusion, Chronic Kidney Disease.

  • Is Bayer publicly traded?

    Bayer appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Bayer develop or market?

    We link 62 drug profile(s) where Bayer is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/bayer-ag#company-drugs.

  • What are the latest developments for Bayer?

    In the last 12 months our linked public records show 47 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Bayer focus on?

    Bayer focuses on Chronic kidney disease, Advanced solid tumors, Heart failure due to systemic left ventricular systolic dysfunction based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
38
Oncology
18
Cardiology
15
Infectious Disease
3
Neurology
1